Toll-like Receptor Ligands Energize Peptide Vaccines Through Multiple Paths.
From: Immunology Program and Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA. ecelis@moffitt.org
Cancer research
- Publish Date: Sep 2007
- ISSN: 0008-5472
- Volume: 67
- Issue: 17
- Pages: 7945-7
- Medium: Print
- Language: English
- Citation (JAMA): Celis Esteban, et al. Toll-like Receptor Ligands Energize Peptide Vaccines Through Multiple Paths.. Cancer Res. Sep 2007;67:7945-7
Abstract
The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.
Mesh Headings (Keywords): Adjuvants, Immunologic, Animals, Breast Neoplasms, Cancer Vaccines, Humans, Immunotherapy, Ligands, Models, Biological, Neoplasms, Signal Transduction, T-Lymphocytes, Cytotoxic, Toll-Like Receptors, Vaccines, Subunit
Check for Full Text / PubMed Unique Identifier (PMID): 17804699
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.